General Information of Drug (ID: DMU6WR9)

Drug Name
AMG-247 Drug Info
Synonyms AMG-369; Multiple sclerosis therapeutics, Amgen; S1P1 receptor antagonists (multiple sclerosis/inflammation); S1P1 receptor antagonists (multiple sclerosis/inflammation), Amgen
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Investigative [1]
Cross-matching ID
TTD Drug ID
DMU6WR9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [2]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [3]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [4]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [5]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [6]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [7]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [8]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [8]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [9]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
8 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
9 Clinical pipeline report, company report or official report of Ventyx Biosciences
10 Clinical pipeline report, company report or official report of Connect Biopharma